Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if sunitinib malate (SU011248) can help
to control VHL. The safety of this drug will also be studied.
Primary objectives:
- Evaluate safety of treatment with SU011248/sunitinib malate (50 mg daily dose for 4
weeks, then 2 weeks off) for 6 months in patients with Von Hippel-Lindau Syndrome (VHL)
who have a measurable lesion undergoing surveillance
Secondary objectives:
- Evaluate efficacy of treatment with SU011248/sunitinib malate (50 mg daily dose for 4
weeks, then 2 weeks off) for 6 months in patients with VHL who have a measurable lesion
undergoing surveillance
Correlative objectives:
- Evaluate quality of life of SU011248/sunitinib malate therapy in VHL patients
- Evaluate peripheral blood lymphocyte receptor phosphorylation in VHL patients taking
SU011248/sunitinib malate (optional procedure)
- Correlate results of dynamic contrast-enhanced and diffusion weighted MRI and dynamic
contrast enhanced CT with response and explore findings suggestive of surrogates of
early response (optional procedure)